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A B S T R A C T   
Objectives: Maternal serum inhibin-A, pregnancy associated plasma protein-A (PAPP-A) and PAPP-A2 together 
with placental growth factor (PlGF), maternal risk factors and uterine artery pulsatility index (UtA PI) were 
analysed to study their ability to predict pre-eclampsia (PE). 
Study design: Serial serum samples for the nested case-control study were collected prospectively at 12–14, 18–20 
and 26–28 weeks of gestation from 11 women who later developed early-onset PE (EO PE, diagnosis < 34 + 0 
weeks of gestation), 34 women who developed late-onset PE (LO PE, diagnosis ≥ 34 + 0 weeks) and 89 controls. 
Main outcome measures: Gestational age -adjusted multiples of the median (MoM) values were calculated for 
biomarker concentrations. Multivariate regression analyses were performed to combine first trimester bio-
markers, previously reported results on PlGF, maternal risk factors and UtA PI. Area under curve (AUC) values 
and 95% confidence intervals (CIs) for the prediction of PE and its subtypes were calculated. 
Results: A high first trimester inhibin-A predicted PE (AUC 0.618, 95%CI, 0.513–0.724), whereas PAPP-A and 
PlGF predicted only EO PE (0.701, 0.562–0.840 and 0.798, 0.686–0.909, respectively). At 26–28 weeks PAPP-A2 
and inhibin-A predicted all PE subtypes. In the multivariate setting inhibin-A combined with maternal pre- 
pregnancy body mass index, prior PE and mean UtA PI predicted PE (0.811,0.726–0.896) and LO PE (0.824, 
0.733–0.914). 
Conclusions: At first trimester inhibin-A show potential ability to predict not only EO PE but also LO PE whereas 
PlGF and PAPP-A predict only EO PE. At late second trimester inhibin-A and PAPP-A2 might be useful for short- 
term prediction of PE.   
Abbreviations: AUC, area under curve; ASA, acetylsalisylic acid; BMI, body mass index; EO PE, early-onset pre-eclampsia (diagnosis < 34 weeks of gestation); IGF, 
insulin-like growth factor; IGFBP, insulin growth factor binding protein; IUGR, intrauterine growth restriction; LO PE, late-onset pre-eclampsia (diagnosis ≥ 34 weeks 
of gestation); MoM, multiples of the median; PAPP-A, plasma protein-A; PAPP-A2, plasma protein-A2; PE, pre-eclampsia; PlGF, placental growth factor; UtA PI, 
uterine artery pulsatility index; ROC, receiver-operating characteristic; SGA, small for gestational age. 
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1. Introduction 
Early identification of women destined to develop pre-eclampsia 
(PE) later in pregnancy would enable preventive interventions such as 
low-dose acetylsalicylic acid (ASA) and more intensive follow-up of 
these women [1–3]. The most promising predictive model includes a 
combination of first trimester serum placental growth factor (PlGF) and 
the maternal clinical risk factors such as pre-pregnancy body mass index 
(BMI), maternal age and a history of PE. The accuracy could be slightly 
improved by adding pregnancy-associated plasma protein-A (PAPP-A) 
and uterine artery pulsatility index (UtA PI) measured by doppler ul-
trasound [4]. The ability of this model to predict early-onset PE (EO PE) 
(diagnosis < 34 weeks of gestation) is fairly good. However, its clinical 
use is limited because its modest value in predicting late-onset PE (LO 
PE), which is the most common subtype of PE [4]. 
Inhibin-A is a glycoprotein hormone produced by placental tropho-
blasts [5,6]. It is used in the second trimester combined screening of 
chromosomal abnormalities [7]. Several studies have shown that 
women who developed PE have higher levels of inhibin-A already in the 
first trimester [6,8,9]. However, its sensitivity has been found to be too 
low for use as a single marker to predict PE [10]. 
PAPP-A is mainly produced by placental syncytiotrophoblasts 
[11,12] and low levels are associated with pregnancy complications 
such as PE, small-for-gestational age (SGA), preterm delivery and 
spontaneous abortion [13–15]. Pregnancy-associated plasma protein-A2 
(PAPP-A2) is a homologue of PAPP-A sharing 46% amino acid similarity 
[16]. PAPP-A2 is also expressed by the syncytiotrophoblasts [17–19] 
and it cleaves specifically insulin-like growth factor-binding protein 5 
(IGFBP-5) while PAPP-A cleaves insulin-like IGFBP-4 [16]. In contrast to 
PAPP-A, the cleavage of IGFBP-5 by PAPP-A2 does not require the 
presence of IGF [16], which is essential for normal placentation [20]. 
Maternal serum concentration of PAPP-A2 has been shown to be 
significantly higher in manifest PE than in uncomplicated pregnancy 
[19,21,22]. PAPP-A2 plays a role in normal placentation and alterations 
in its concentration may be implicated in pregnancy complications [23]. 
We studied whether inhibin-A, PAPP-A, and PAPP-A2 analysed at 
three timepoints during first and second trimesters serve as potential 
biomarkers to predict PE and its subtypes. The results were compared 
with the previously reported PlGF results [24]. All first trimester bio-
markers were also analysed together with the maternal clinical risk 
factors and UtA PI. 
2. Methods 
2.1. Subjects 
Women in the present nested case-control study participated in the 
PREDO (Prediction and Prevention of Pre-eclampsia and Intrauterine 
Growth Restriction) project [25]. Women with clinical risk factors for PE 
were prospectively recruited between September 2005 and December 
2009 at ten participating maternity clinics in Finland. The ethics Com-
mittee at Helsinki and Uusimaa Hospital District approved the study and 
written informed consent was obtained from all participants. 
A subcohort of 134 women was included in this study: 45 women 
diagnosed with PE and 89 controls who did not develop PE (49 with and 
40 without known clinical risk factors for PE). In the pre-eclampsia 
group, 11 had early-onset PE (EO PE, diagnosis < 34 + 0 weeks of 
gestation) and 34 had late-onset PE (LO PE, diagnosis ≥ 34 + 0 weeks). 
Eight women who developed PE participated in low-dose ASA trial of the 
PREDO project. They were treated with low-dose ASA 100 mg/day from 
12th to 35th week of gestation. Equal numbers of women who received 
low-dose ASA and did not develop PE were included as controls. Other 
controls were chosen based on sample availability. 
Inclusion criteria for women with clinical risk factors for PE were as 
follows: PE, intrauterine growth restriction (IUGR), gestational diabetes 
or foetal demise in a previous pregnancy; pre-pregnancy obesity (BMI ≥
30 kg/m2); chronic hypertension; type 1 diabetes; maternal age at 
childbirth < 20 years or > 40 years; systemic lupus erythematosus (SLE) 
or Sjögren’s syndrome [25]. 
PE was defined as systolic blood pressure ≥ 140 mmHg and/or 
diastolic blood pressure ≥ 90 mmHg occurring after 20th weeks of 
gestation and proteinuria (≥300 mg per 24 h or the dipstick equivalent 
in two consecutive measurements [26]. Women with pre-eclampsia 
superimposed on chronic hypertension were included in the PE group. 
SGA was defined as birthweight lower than − 2 SD adjusted for sex and 
gestational age according to Finnish birth weight charts [27]. 
Blood samples were obtained at three timepoints during pregnancy 
(12–14, 18–20 and 26–28 weeks of gestation). Mean UtA PI was 
measured by doppler ultrasound in all participants at 12–14 weeks of 
gestation [2]. 
2.2. Laboratory methods 
Serum was separated by centrifugation within 1 h and aliquots were 
stored at − 80 ◦C until analyses [25]. Serum inhibin-A, PAPP-A and 
PAPP-A2 concentrations were measured by ELISA Kits according to 
manufacturer’s instructions (Ansh Labs, Webster, USA) from total of 372 
serum samples. Inter-assay coefficients of variation (CV) were 10.9% (at 
control concentration of 110 pg/ml) and 4.9% (at control concentration 
of 344 pg/ml) for inhibin-A; 2.3% (at control concentration of 310 ng/ 
ml) and 15.8% (at control concentration of 1150 ng/ml) for PAPP-A, and 
8.9% (at control concentration of 0.9 ng/ml) and 19.5% (at control 
concentration of 3 ng/ml) for PAPP-A2. PlGF concentrations were 
analysed by a Delfia method Kits as described previously (PerkinElmer, 
Turku, Finland) [24]. 
2.3. Statistics 
Continuous variables between groups were compared using the 
Mann-Whitney U test and categorical variables were compared using the 
Chi-Square test. Correlations between continuous variables were ana-
lysed using Pearson’s correlation. Change of biomarker concentration 
during advancing pregnancy between two sampling points were ana-
lysed using Wilcoxon signed rank test for paired samples. The results 
were expressed as mean ± SDs, median and 95% confidence intervals 
(CIs) or interquartile range (IQR) when appropriate. Concentrations 
were log10 transformed and normality was tested according to the 
Kolmogorov-Smirnov’s test. To adjust the concentrations for gestational 
age, multiples of the median (MoM) values were calculated for each 
biomarker: the linear regression equation calculated at three different 
time points from the samples collected from 40 controls without risk 
factors from log10 transformed values. For the prediction of PE, clinical 
background factors (maternal age, pre-pregnancy BMI, prior PE, prior 
SGA, prior foetus mortus, type 1 diabetes, primiparity, chronic hyper-
tension), biomarkers at 12–14 weeks of gestation and UtA PI were 
analysed by logistic regression using forward stepwise method where 
variables with p < 0.10 were included in model. The diagnostic accuracy 
for separate biomarkers and for the combinations of clinical risk factors 
and biomarkers were analysed using receiver-operating characteristic 
(ROC) curve analysis and expressed as the area under the curve (AUC). 
Analyses were performed using SPSS Statistics version 25 (IBM). Two- 
sided P values < 0.05 were considered statistically significant. 
The power of the study was calculated using previous results on PlGF 
for prediction of EO PE [24]. With these mean MoM values and SDs the 
power was 98.6% to detect differences between the groups (9 women 
with EO PE and 67 controls) with two-sided p-value < 0.05. 
3. Results 
3.1. Clinical characteristics 
Clinical characteristics of the study groups are presented in Table 1. 
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There were no significant differences in gestational age at sampling 
between the study groups (data not shown). Eight women who devel-
oped both subsequent PE and SGA were analysed as a separate subgroup 
(data not shown). 
3.2. MoMs for biomarker concentrations 
Inhibin-A concentration decreased from 12 to 14 to 18–20 weeks of 
gestation and increased after that (p < 0.001 for controls and p = 0.001 
for PE) in all groups (p < 0.001 for both) (Supplementary Fig. 1A). 
Inhibin-A concentration was higher than in controls at 18–20 and 26–28 
weeks (Table 2A) and the MoM values were higher than in controls at all 
studied gestational weeks in women with subsequent PE (Table 2B). 
Inhibin-A MoM values were higher at 18–20 and 26–28 weeks in women 
with subsequent EO PE and at 26–28 weeks in women with LO PE 
compared to controls (Table 2B). 
PAPP-A concentrations increased during advancing pregnancy in all 
groups (p < 0.001 for all) (Supplementary Fig. 1B). Women developing 
EO PE had lower PAPP-A concentrations and MoM values than controls 
at 12–14 weeks of gestation (Table 2A and 2B), 
PAPP-A2 concentrations increased during advancing pregnancy in 
all groups (p < 0.001 for all) (Supplementary Fig. 1C). PAPP-A2 con-
centrations and MoM values were higher in women with subsequent PE 
as compared to controls at 26–28 weeks. Higher PAPP-A2 MoM values 
were observed already at 18–20 weeks in women with subsequent EO PE 
(Table 2A and 2B). 
Inhibin-A concentrations and MoM values were higher in women 
with subsequent PE with SGA already at 12–14 weeks of gestation. 
Higher PAPP-A2 MoM values were observed already at 18–20 weeks in 
women with subsequent PE with SGA (p < 0.001) in addition to 26–28 
weeks of gestation (data not shown). 
Table 1 
Clinical characteristics.   
Controls PE   
All EO PE LO PE  
N ¼ 89 N ¼ 45 N ¼ 11 N ¼ 34 
Characteristics Mean / N SD / % Mean / N SD / % Mean / N SD / % Mean / N SD / % 
Maternal age at entry, years 31.8 5.1 31.3 5.2 31.8 4.6 31.2 5.4 
Pre-pregnancy BMI, kg/m2 25.4 6.4 29.6 7.0a 29.4 7.3 29.7 7.0 a 
Primipara, N 32 36.0 13 28.9 5 45.5 8 23.5 
Blood pressure systolic, mmHg 133 19 170 18 a 180 17b 167 17b 
Blood pressure diastolic. mmHg 86 12 106 10b 110 10b 105 11b 
Proteinuria max, g / 24 h   2.8 3.4 5.3 4.3 1.8 2.4 
Gestational age at delivery, weeks 39.4 1.5 37.0 3.4b 32.2 3.3b 38.5 1.4 a 
Birth weight, g 3482 450 2941 989 a 1744 1052b 3328 581 
Birth weight, SD − 0.17 0.90 − 0.73 1.39 a − 1.85 1.55b − 0.36 1.12 
Placenta, g 594 140 540 155 364 82b 594 130 
EO PE (<34 wk), N 0 0.0 11 24.4 11 100.0 0 0.0 
Preterm PE (<37 wk), N 0 0.0 13 28.9 11 100.0 0 0.0 
Chronic hypertension, N 12 13.5 13 28.9 a 4 36.4 9 26.5 
Gestational hypertension, N 7 7.9 0 0.0 0 0.0 0 0.0 
Gestational diabetes, diet, N 14 15.7 11 24.4 2 18.2 9 26.5 
Gestational diabetes, insulin, N 4 4.5 1 2.2 0 0.0 1 2.9 
HELLP syndrome, N 0 0.0 3 6.7 a 2 18.2 1 2.9 
SGA, N 1 1.1 8 17.8 a 6 54.5b 2 5.9 
P value a < 0.05 or b < 0.001 compared to controls based on Mann-Whitney U test for continuous variables or Chi-Square test for categorical variables. PE = pre- 
eclampsia, EO PE = early-onset pre-eclampsia (diagnosis < 34 weeks of gestation), LO PE = late-onset pre-eclampsia (diagnosis ≥ 34 weeks of gestation), BMI = body 
mass index, HELLP = haemolysis, elevated liver enzymes, low platelets, SGA = small-for-gestational age. 
Table 2A 
Concentrations of serum Inhibin-A, pregnancy associated plasma protein-A (PAPP-A) and pregnancy associated plasma protein-A2 (PAPP-A2).     
Controls PE EO PE LO PE  
Weeks N Median N Median P N Median P N Median P    
IQR  IQR   IQR   IQR  
Inhibin-A 12–14 88 277 41 367  0.058 10 378  0.127 31 341  0.138 
(pg/mL)   200–410  251–499   274–378   248–496   
18–20 89 195 43 227  0.008 11 340  0.001 32 213  0.148    
139–253  186–353   216–340   178–283   
26–28 88 346 40 507  <0.001 8 1250  <0.001 32 430  0.006    
269–466  355–839   554–1250   344–695  
PAPP-A2 12–14 88 21.3 41 22.4  0.925 10 22.1  0.814 31 22.4  0.993 
(ng/mL)   16.3–27.4  13.6–34   12.9–22.1   13.6–34.1   
18–20 89 22.6 43 25.8  0.213 11 57.6  0.007 32 24.4  0.937    
16.7–31.1  16.3–40.8   19.2–57.6   15.3–30.1   
26–28 88 36.1 41 46.6  0.002 9 236  <0.001 32 41  0.058    
25.2–51.6  32–132.7   133–236   30.4–71  
PAPP-A 12–14 88 129 41 99.9  0.275 10 71.7  0.038 31 121  0.811 
(ng/mL)   72.9–185  67.3–163   62.6–71.7   74–182   
18–20 89 621 43 653  0.582 11 569  0.796 32 661  0.597    
464–938  387–934   355–569   391–895   
26–28 88 1392 41 1236  0.251 9 1170  0.494 32 1276  0.307    
1006–2271  767–2052   537–1170   790–2005  
P value based on Mann-Whitney U test as compared to controls. PE = pre-eclampsia, EO PE = early-onset pre-eclampsia (diagnosis < 34 weeks of gestation), LO PE =
late-onset pre-eclampsia (diagnosis ≥ 34 weeks of gestation), IQR = interquartile range. 
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3.3. Prediction of PE, EO PE and LO PE 
The AUC values for all studied biomarkers including previous data 
on PlGF [24) are shown in Table 3. The AUC value for the prediction of 
all subtypes of PE at 12–14 weeks of gestation was 0.618 for inhibin-A 
and it improved during advancing pregnancy (0.643 at 18–20 weeks 
and 0.717 at 26–28 weeks of gestation). PAPP-A2 predicted PE at 26–28 
weeks (AUC 0.700) and PlGF at 18–20 and 26–28 weeks (AUC 0.648 and 
0.733, respectively) (Table 3). 
Only PAPP-A and PlGF showed utility to predict EO PE at 12–14 
weeks of gestation (AUC 0.701 and 0.798, respectively). Inhibin-A, 
PAPP-A2 and PlGF showed ability to predict EO PE at 18–20 weeks 
and 28–26 weeks of gestation. Inhibin-A, PAPP-A2 and PlGF predicted 
LO PE at 26–28 weeks of gestation (Table 3). 
3.4. Multivariate analyses at 12–14 weeks of gestation 
The combinations of the studied biomarkers, previous data on PlGF, 
maternal clinical risk factors and UtA PI were studied using stepwise 
forward logistic regression analysis (Table 4). The MoM for Inhibin-A 
and PAPP-A showed capacity to predict PE with an AUC value for the 
combination of 0.694. AUC value for BMI, prior PE and UtA PI was 
0.796. Combination of Inhibin-A MoM with pre-pregnancy BMI, prior 
PE, and UtA PI gave an AUC value of 0.811 (Table 4, Fig. 1). 
Of the studied biomarkers, PAPP-A MoM and PlGF MoM predicted 
EO PE (AUC 0.701 and 0.798, respectively). AUC value for BMI, prior 
SGA and UtA PI was 0.825.Combining PlGF MoM with information of 
prior SGA, pre-pregnancy BMI, and UtA PI gave an AUC value 0.906 for 
prediction of EO PE. PlGF MoM and clinical risk factors were superior to 
PAPP-A MoM to predict EO PE in the multivariate setting (Table 4, 
Supplementary Fig. 2). 
None of the studied biomarkers alone predicted LO PE. Combining 
Table 2B 
Multiples of the median (MoM) values of serum Inhibin-A, pregnancy associated plasma protein-A (PAPP-A) and PAPP-A2.     
Controls PE EO PE LO PE   
N Median N Median P N Median P N Median P  
Weeks  IQR  IQR   IQR   IQR  
Inhibin-A 12–14 87 1.01 41 1.16  0.031 10 1.26  0.169 31 1.15  0.062 
MoM   0.68–1.37  0.91–1.8   0.84–1.59   0.96–1.83   
18–20 88 0.96 43 1.12  0.008 11 1.77  0.001 32 1.06  0.144    
0.69–1.28  0.94–1.77   1.08–2.44   0.9–1.39   
26–28 87 0.9 40 1.3  <0.001 8 3.31  <0.001 32 1.13  0.004    
0.7–1.2  0.93–2.08   1.43–9.56   0.9–1.8  
PAPP-A2 12–14 87 1.03 41 1.02  0.826 10 1.11  0.713 31 1.02  0.651 
MoM   0.76–1.33  0.63–1.44   0.58–1.71   0.63–1.37   
18–20 88 1.06 43 1.17  0.237 11 2.59  0.008 32 1.11  0.995    
0.77–1.43  0.73–1.84   0.88–4.57   0.68–1.36   
26–28 87 1.08 41 1.67  <0.001 9 6.63  <0.001 32 1.39  0.015    
0.68–1.53  1.02–3.77   4.15–13.46   1–2.03  
PAPP-A 12–14 87 0.82 41 0.65  0.072 10 0.57  0.038 31 0.73  0.278 
MoM   0.53–1.12  0.45–0.98   0.42–0.63   0.46–1.06   
18–20 88 0.83 43 0.88  0.447 11 0.73  0.73 32 0.89  0.462    
0.63–1.26  0.54–1.26   0.49–1.35   0.54–1.09   
26–28 87 0.85 41 0.78  0.299 9 0.77  0.517 32 0.8  0.362    
0.63–1.36  0.49–1.15   0.32–2.11   0.52–1.09  
PlGF 12–14 67 0.98 39 0.89  0.25 9 0.73  0.004 30 0.93  0.975 
MoM   0.76–1.22  0.71–1.15   0.55–0.84   0.81–1.22   
18–20 70 0.89 38 0.77  0.011 10 0.36  <0.001 28 0.84  0.436    
0.74–1.2  0.44–1.05   0.19–0.59   0.7–1.21   
26–28 68 0.93 34 0.55  <0.001 8 0.14  <0.001 26 0.73  0.009    
0.65–1.32  0.23–0.98   0.07–0.23   0.41–1.01  
P values are based on Mann-Whitney U test as compared to controls. PE = pre-eclampsia, EO PE = early-onset pre-eclampsia (diagnosis < 34 weeks of gestation), LO PE 
= late-onset pre-eclampsia (diagnosis ≥ 34 weeks of gestation), IQR = interquartile range. MoM values are based on concentrations of markers analysed from women 
without risk factors of PE and who did not develop PE (n = 40) by linear regression analysis using log10 transformed values. 
Table 3 
The area under the curve (AUC) values from receiver operating characteristic (ROC) curve and 95% confidence intervals (CIs) of different biomarkers in the prediction 
of pre-eclampsia and its subgroups.    
PE EO PE LO PE  
Weeks AUC 95% CI P AUC 95% CI P AUC 95% CI P 
Inhibin-A 12–14 0.618 0.513 0.724 0.031 0.633 0.456 0.810 0.169 0.613 0.495 0.732 0.062 
MoM 18–20  0.643  0.542  0.745  0.008  0.807  0.668  0.946  0.001  0.587  0.472  0.703  0.144  
26–28  0.717  0.621  0.813  <0.001  0.889  0.764  1.000  <0.001  0.674  0.567  0.782  0.004 
PAPP-A2 12–14  0.488  0.374  0.602  0.826  0.536  0.310  0.762  0.713  0.473  0.347  0.598  0.651 
MoM 18–20  0.564  0.452  0.675  0.237  0.748  0.529  0.967  0.008  0.500  0.382  0.619  0.995  
26–28  0.700  0.596  0.804  <0.001  0.891  0.698  1.000  <0.001  0.646  0.532  0.761  0.015 
PAPP-A 12–14  0.599  0.496  0.701  0.072  0.701  0.562  0.840  0.038  0.566  0.451  0.680  0.278 
MoM 18–20  0.541  0.431  0.651  0.447  0.532  0.320  0.744  0.730  0.544  0.423  0.665  0.462  
26–28  0.557  0.447  0.667  0.299  0.566  0.320  0.812  0.517  0.555  0.437  0.672  0.362 
PlGF 12–14  0.567  0.452  0.682  0.250  0.798  0.686  0.909  0.004  0.498  0.371  0.625  0.975 
MoM 18–20  0.648  0.535  0.761  0.011  0.921  0.846  0.997  <0.001  0.551  0.421  0.680  0.436  
26–28  0.733  0.628  0.837  <0.001  0.925  0.792  1.000  <0.001  0.674  0.555  0.793  0.009 
The AUC and P values are based on receiver operating characteristics (ROC) curve compared to controls (n = 89). PE = pre-eclampsia, EO PE = early-onset pre- 
eclampsia (diagnosis < 34 weeks of gestation), LO PE = late-onset pre-eclampsia (diagnosis ≥ 34 weeks of gestation), MoM = multiples of median, PAPP-A =
pregnancy associated plasma protein-A, PlGF = placental growth factor. 
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inhibin-A MoM with pre-pregnancy BMI, information of prior PE, and 
UtA PI the AUC value to predict LO PE was 0.824. Combination of 
clinical risk factors and UtA PI without inhibin-A gave an AUC value of 
0.807 and when UtA PI was removed the AUC value for the combination 
of inhibin-A and clinical risk factors was 0.815 (Table 4, Supplementary 
Fig. 3). 
In women who developed PE with SGA Inhibin-A MoM combined 
with information about chronic hypertension and UtA PI gave an AUC 
value of 0.857 (95% CI 0.724–0.990; p = 0.001). In a multivariate 
setting with clinical risk factors Inhibin-A performed better than PlGF in 
predicting PE with SGA (data not shown). 
3.5. Correlations 
At 12–14 weeks, PAPP-A and PAPP-A2 correlated negatively with 
maternal pre-pregnancy BMI and PAPP-A2 correlated positively with 
chronic hypertension status. Otherwise, the markers studied were in-
dependent of maternal age, parity, pre-pregnancy BMI and chronic hy-
pertension. When comparing inhibin-A, PAPP-A2 and PAPP-A 
concentrations between ASA and placebo users in women with subse-
quent PE, EO PE or LO PE, among women with subsequent PE, inhibin-A 
at 18–20 weeks of gestation was slightly lower in women having ASA 
than in women receiving placebo (MoM values: 0.94, 0.76 – 1.26; me-
dian, IQR; vs. 1.58, 1.17–2.86; p = 0.006). Other biomarker concen-
trations did not differ between ASA and placebo users (data not shown). 
4. Discussion 
We found that inhibin-A together with clinical risk factors and UtA PI 
performed well in the prediction of PE, especially LO PE was predicted 
already at 12–14 weeks of gestation. Previously established biomarkers, 
Table 4 
The area under the curve (AUC) values from receiver operating characteristic (ROC) curve for combinations of maternal clinical risk factors, studied biomarkers and 
uterine artery pulsatility index (UtA PI) at 12–14 weeks of pregnancy in predicting of pre-eclampsia (PE), early-onset pre-eclampsia (EO PE) and late-onset pre- 
eclampsia (LO PE).   
Model Variables N AUC 95%CI P value 
PE Clinical risk factorsa BMI + prior PE 44  0.769 0.684–0.853  <0.001   
BMI 44  0.684 0.587–0.782  0.001   
Prior PE 45  0.666 0.563–0.769  0.002  
Doppler US UtA PI 39  0.629 0.520–0.739  0.023  
Combination BMI + prior PE + UtA PI 38  0.796 0.715–0.878  <0.001  
Biomarkersb Inhibin-A + PAPP-A 41  0.694 0.597–0.792  <0.001  
Allc BMI + prior PE + Inhibin-A + UtA PI 31  0.811 0.726–0.896  <0.001 
EO PE Clinical risk factorsa Prior SGA + BMI 11  0.734 0.599–0.869  0.012   
BMI 11  0.687 0.530–0.844  0.044   
Prior SGA 11  0.591 0.397–0.786  0.324  
Doppler US UtA PI 8  0.780 0.670–0.890  0.009  
Combination Prior SGA + BMI + UtA PI 8  0.825 0.724–0.926  0.003  
Biomarkersb PlGF 9  0.798 0.686–0.909  0.004  
Allc Prior SGA + BMI + PlGF + UtA PI 6  0.906 0.824–0.988  0.001 
LO PE Clinical risk factorsa BMI + prior PE 33  0.777 0.685–0.869  <0.001   
BMI 33  0.684 0.573–0.794  0.002   
Prior PE 34  0.683 0.569–0.796  0.002  
Doppler US UtA PI 31  0.590 0.467–0.714  0.142  
Combination BMI + prior PE + UtA PI 30  0.807 0.723–0.892  <0.001  
Biomarkersb Inhibin-A 31  0.613 0.495–0.732  0.062  
Allc BMI + prior PE + Inhibin-A + UtA PI 27  0.824 0.733–0.914  <0.001  
All (excluding UtA PI)c BMI + prior PE + Inhibin-A 30  0.815 0.730–0.900  <0.001 
The area under the curve (AUC) and P values are based on receiver operating characteristics (ROC) curve compared to controls (n = 89). Combinations are analysed 
using logistic regression analysis stepwise forward method where variables with p < 0.10 are included to model. 95% CI = confidence interval, PE = pre-eclampsia, US 
= ultrasound, EO PE = early-onset pre-eclampsia (diagnosis < 34 weeks of gestation), LO PE = late-onset pre-eclampsia (diagnosis ≥ 34 weeks of gestation). 
a Clinical background factors include: maternal age, pre-pregnancy body-mass-index (BMI), prior pre-eclampsia, prior small-for-gestational age, prior foetus mortus, 
type 1 diabetes, primiparity, chronic hypertension.  
b Inhibin-A, pregnancy associated plasma protein-A2 (PAPP-A2), pregnancy associated plasma protein-A (PAPP-A) and placental growth factor (PlGF)  
c Clinical risk factors, Inhibin-A, PAPP-A2, PAPP-A and PlGF and uterine artery pulsatility index (UtA PI).  
Fig. 1. Receiver operating characteristics (ROC) curve for the prediction of pre- 
eclampsia (PE) using biomarkers alone or combined with clinical risk factors 
and uterine artery pulsatility index (UtA PI) at 12–14 weeks of gestation. BMI 
= body-mass-index, PE = pre-eclampsia, UtA PI = uterine artery pulsatility 
index, PAPP-A = pregnancy associated plasma protein-A, PlGF = placental 
growth factor. 
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PlGF and PAPP-A, showed advantage only for the prediction of EO PE. 
In line with earlier studies, inhibin-A concentration decreased after 
the first trimester and increased after midgestation [5] and was higher in 
women with subsequent PE compared to controls [6,9,28]. Our study 
revealed that inhibin-A was better than PlGF and PAPP-A for prediction 
of LO PE at 12–14 weeks of gestation but it did not predict EO PE. In a 
previous meta-analysis, the sensitivity of inhibin-A to predict EO PE was 
only 32% (95% CI, 25–39%) with a specificity of 90% [10] and to the 
best of our knowledge its utility to predict LO PE has not been examined 
in earlier studies. Inhibin-A is an endocrine regulator of the gonadal and 
placental function [5,6,29]. In pre-eclamptic pregnancies the produc-
tion of inhibin-A in placental trophoblasts have been shown to be 
increased compared to normal placentas with unknown mechanism 
[30,31]. 
In the present study concentrations of PAPP-A and PAPP-A2 
increased during advancing gestation in women with or without sub-
sequent PE. This is in agreement with the results of earlier studies 
[32,33]. Our study demonstrates that low levels of PAPP-A at 12–14 
weeks of gestation are associated with increased risk of EO PE. This has 
also been seen in earlier studies [9,14,34,35]. In a multivariate analysis 
PAPP-A did not improve the prediction of all PE or EO PE when using the 
combination of maternal serum PlGF or inhibin-A, maternal character-
istics, obstetric history and uterine artery PI. This is in line with several 
earlier studies [4,36,37]. Other studies have shown association of early 
pregnancy low PAPP-A levels with other placental disease such as SGA 
and preterm delivery [14,15,34]. Low PAPP-A levels also correlate more 
strongly to EO PE than LO PE [35]. These studies support the notion of 
PAPP-A rather being a serum marker for placental disease in general 
than being specific for PE because most of the women with EO PE have 
placental dysfunction and SGA foetus. PAPP-A is an IGFBP-4 proteinase 
and the presence of IGF is obligatory for its proteolytic function [38]. 
IGFs have an important role in the regulation of trophoblast invasion 
[34]. Low PAPP-A levels may rather be a cause than a consequence in 
early placental dysfunction. 
In the present study increased concentration of PAPP-A2 was asso-
ciated with all studied PE subtypes at 18–20 and 26–28 weeks of 
gestation. Increased concentrations have been shown previously in 
subsequent [22] and established PE [19,32]. In contrast to PAPP-A, the 
cleavage of IGFBP-5 by PAPP-A2 does not require the presence of IGF 
[16]. Hypoxia, which is known to occur in the PE placenta, has been 
shown to upregulate the expression of PAPP-A2 mRNA in placental ex-
plants [21] and placental cell lines (BeWo cells) in cell culture [39]. 
These findings suggest that increased PAPP-A2 serum levels are more 
likely to be a consequence of placental pathology than vice versa. Thus, 
PAPP-A2 may be more sensitive and specific for PE than PAPP-A. 
In the prediction of all PE and EO PE, Inhibin-A [40] and PAPP-A2 
showed similar ability with PlGF at 26 to 28 weeks of gestation. PlGF 
can be used in short-term prediction of PE with or without soluble fms- 
like tyrosine kinase-1 (sFlt-1) [41,42]. Our study suggests that inhibin-A 
and PAPP-A2 may, as well, have potential for short-term prediction of 
PE among women having suspected symptoms of PE. 
The strength of our study is the prospectively recruited, well- 
characterised cohort with three consecutive serum samples from the 
same individuals. Its main weakness is the relatively small sample size 
and the phenomenon that ASA might have had an effect on biomarker 
concentrations at 18–20 and 26–28 weeks of gestation and development 
of PE. However, the difference between ASA and placebo users was 
observed only in concentrations of inhibin-A at 18–20 weeks in women 
with subsequent PE with unknown mechanism. 
In conclusion, this study showed that inhibin-A with maternal clin-
ical risk factors and UtA PI show potential ability to predict all PE and LO 
PE at 12–14 weeks of gestation whereas PlGF was superior for predicting 
EO PE. PAPP-A2 and inhibin-A show potential capacity for short-term 
prediction of PE at 26–28 weeks of gestation. 
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